<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58766">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02340975</url>
  </required_header>
  <id_info>
    <org_study_id>D4190C00021</org_study_id>
    <nct_id>NCT02340975</nct_id>
  </id_info>
  <brief_title>A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma</brief_title>
  <official_title>A Phase 1b/2 Study of MEDI4736 in Combination With Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects With Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, multicenter, open-label, dose-exploration and dose-expansion study to
      evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and
      immunogenicity of MEDI4736 in combination with tremelimumab, MEDI4736 monotherapy or
      tremelimumab monotherapy in subjects with metastatic or recurrent gastric or
      gastroesophageal junction adenocarcinoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2015</start_date>
  <completion_date type="Anticipated">August 17, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 17, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number (percentage) of subjects reporting adverse events and number (percentage) of subjects reporting serious adverse events.</measure>
    <time_frame>Follow-up 3 months after the last dose of study medication</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects experiencing dose-limiting toxicities</measure>
    <time_frame>First dose of study medications through 4 weeks after the first dose of study medication</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Objective Response Rate</measure>
    <time_frame>Followed through 5 years after the last subject receives the first dose of study medication</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Progression Free Survival at 6 months</measure>
    <time_frame>Followed through 5 years after the last subject receives the first dose of study medication</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Objective Response Rate</measure>
    <time_frame>Follow up through 5 years after the last subject receives the first dose of study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Progression Free Survival at 6 months</measure>
    <time_frame>Follow up through 5 years after the last subject receives the first dose of study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>Follow up through 5 years after the last subject receives the first dose of study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD-L1 expression</measure>
    <time_frame>Follow up through 3 months after last dose of study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Follow up through 5 years after the last subjects receives the first dose of study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Follow up through 5 years after the last subject receives the first dose of study medication</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Gastric or Gastroesophageal Junction Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>MEDI4736 + tremelimumab (Arm A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Second line subjects with metastatic or recurrent gastric or GEJ adenocarcinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI4736 (Arm B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Second line subjects with metastatic or recurrent Gastric or GEJ adenocarcinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tremelimumab (Arm C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Second line subjects with metastatic or recurrent Gastric or GEJ adenocarcinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI4736 + tremelimumab (Arm D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Third line subjects with metastatic or recurrent Gastric or GEJ adenocarcinoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI4736 + tremelimumab</intervention_name>
    <description>MEDI4736 will be administered by IV infusion in combination with tremelimumab.</description>
    <arm_group_label>MEDI4736 + tremelimumab (Arm A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI4736</intervention_name>
    <description>MEDI4736 will be administered by IV infusion.</description>
    <arm_group_label>MEDI4736 (Arm B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tremelimumab</intervention_name>
    <description>Tremelimumab will be administered by IV infusion.</description>
    <arm_group_label>Tremelimumab (Arm C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI4736 + tremelimumab</intervention_name>
    <description>MEDI4736 will be administered by IV infusion in combination with tremelimumab</description>
    <arm_group_label>MEDI4736 + tremelimumab (Arm D)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects

          2. 18 years and older

          3. Histological or cytological confirmation of metastatic or recurrent gastric or
             gastroesophageal junction adenocarcinoma

          4. Subjects must have received and have progressed, or are refractory to standard
             regimens

          5. Prior lines of therapy:

               1. For Phase 1b and: Must have received and have progressed, or are refractory to
                  one systemic platinum- or fluoropyrimidine-based chemotherapy regimen for
                  metastatic or recurrent disease.

               2. For Arms A, B, and C of Phase 2: Must have received and have progressed, or
                  arerefractory to one systemic platinum- or fluoropyrimidine-based chemotherapy
                  regimen for metastatic or recurrent disease, or Must have received and have
                  progressed, or are refractory to one systemic platinumor fluoropyrimidine-based
                  therapy as part of neoadjuvant or adjuvant regimen withrelapse within 6 months
                  of therapy.

               3. For Arm D of Phase 2: Must have received and have progressed, or are refractory
                  totwo systemic regimens (one standard platinum- or
                  fluoropyrimidine-basedchemotherapy regimen and one approved regimen) for
                  metastatic or recurrent disease.

               4. Subjects who have received and have progressed, or are refractory to one
                  systemicplatinum- or fluoropyrimidine-based therapy as part of neoadjuvant or
                  adjuvantregimen with relapse within 6 months will count as a line of therapy in
                  the metastatic/recurrent setting.

        Exclusion Criteria:

          1. Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer
             treatment

          2. Previous immune-mediated therapy

          3. Concurrent or prior use of immunosuppressive medication with 14 days

          4. Active or prior documented autoimmune or inflammatory disease within 3 years with
             some exceptions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MedImmune, LLC MedImmune, LLC</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>AstraZeneca Cancer Study Locator Service</last_name>
    <phone>1-877-400-4656</phone>
    <email>AstraZeneca@emergingmed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greensville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Higashinari-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kawasaki-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koto-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seongnam-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tao-Yuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 16, 2017</lastchanged_date>
  <firstreceived_date>January 14, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric Adenocarcinoma</keyword>
  <keyword>Gastroesophageal Junction Adenocarcinoma</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Antibodies, Monoclonal</keyword>
  <keyword>Tremelimumab</keyword>
  <keyword>MEDI4736</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
